DELTA-TOCOTRIENOLS CAN SUPPORT
INHIBITION OF CELL PROLIFERATION
ATTENUATION OF TUMOR INVASION AND METASTASIS
INCREASE OF miR-451 EXPRESSIONS
REPRESSED EXPRESSION OF MMP-9 &Upa PROTEINS
Introduction to Alzheimer’s Disease andTocotrienol
Alzheimer’s is the 6th leading cause of death in the United States of America. There are around 5.5 million people in the US, suffering from Alzheimer’s, and around two-thirds of Americans who are suffering from this disease are women. It has been estimated that by the end of 2050, around 16 million people will be diagnosed with Alzheimer’s! Also, Alzheimer’s disease is the 6th leading cause of death in the United States as it kills more people each year than breast cancer and prostate cancer combined!
Alzheimer’s is a spectrum of neurodegenerative illnesses defined by clinical symptoms and changes in the brain. The main characteristic of this disease is progressive dementia where the person keeps losing his memory with time and tends to forget even the slightest of things in just a few minutes. This study has been carried out to investigate the role of Tocotrienols as a neuroprotective agent against Alzheimer’s disease.
How does Tocotrienol fightAlzheimer’s Disease?
The current treatment of Alzheimer’s Disease offers only symptomatic relief to the patients suffering. So, an agent that could help suppress the progression of dementia, which is the major characteristic of Alzheimer’s. Hence, in this study, how Tocotrienol tackles the aspects of Alzheimer’s disease were evaluated.
In the preclinical studies, it was observed that Tocotrienols reduced the oxidative stress by acting as a free-radical scavenger, promoting cellular repair, and mitochondrial function. The results of the study demonstrated that Tocotrienols also prevented glutamate-induced neurotoxicity in the brain cells.
To conclude, Tocotrienols have been observed to have the potential to be used as an agent
which can help prevent the Alzheimer’s disease from occurring and progressing in humans.
Reference for the Study in detail:
- Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., et al. Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol. 2010;9:1118–1127. doi: 10.1016/S1474-4422(10)70223-4. [PubMed] [CrossRef] [Google Scholar]
- Rosen C., Hansson O., Blennow K., Zetterberg H. Fluid biomarkers in Alzheimer’s disease—Current concepts. Mol. Neurodegener. 2013;8:20. doi: 10.1186/1750-1326-8-20. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- Teipel S.J., Grothe M., Lista S., Toschi N., Garaci F.G., Hampel H. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med. Clin. N. Am. 2013;97:399–424. doi: 10.1016/j.mcna.2012.12.013. [PubMed] [CrossRef] [Google Scholar]
- Cui Y., Liu B., Luo S., Zhen X., Fan M., Liu T., Zhu W., Park M., Jiang T., Jin J.S. Identification of conversion from mild cognitive impairment to Alzheimer’s disease using multivariate predictors. PLoS ONE. 2011;6:e21896. doi: 10.1371/journal.pone.0021896. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- Sosa-Ortiz A.L., Acosta-Castillo I., Prince M.J. Epidemiology of dementia and Alzheimer’s disease. Arch. Med. Res. 2012;43:600–608. doi: 10.1016/j.arcmed.2012.11.003. [PubMed] [CrossRef] [Google Scholar]
- Alzheimer’s Association 2015 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2015;11:332–384. [PubMed] [Google Scholar]
- Weuve J., Hebert L.E., Scherr P.A., Evans D.A. Deaths in the united states among persons with Alzheimer’s disease (2010–2050) Alzheimers Dement. 2014;10:e40–e46. doi: 10.1016/j.jalz.2014.01.004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- Wimo A., Jonsson L., Bond J., Prince M., Winblad B. The worldwide economic impact of dementia 2010. Alzheimer’s Dement. 2013;9:1–11.e13. doi: 10.1016/j.jalz.2012.11.006. [PubMed] [CrossRef] [Google Scholar]
- Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dement. 2007;3:186–191. doi: 10.1016/j.jalz.2007.04.381. [PubMed] [CrossRef] [Google Scholar]
- Kumar A., Singh A., Ekavali A review on Alzheimer’s disease pathophysiology and its management: An update. Pharmacol. Rep. 2015;67:195–203. doi: 10.1016/j.pharep.2014.09.004. [PubMed] [CrossRef] [Google Scholar]
- Ghezzi L., Scarpini E., Galimberti D. Disease-modifying drugs in Alzheimer’s disease. Drug Des. Dev. Ther. 2013;7:1471–1478. [PMC free article] [PubMed] [Google Scholar]
- Rondanelli M., Faliva M.A., Peroni G., Moncaglieri F., Infantino V., Naso M., Perna S. Focus on the pivotal role of dietary intake (diet and supplement) and blood levels of tocopherols and tocotrienols in obtaining successful aging. Int. J. Mol. Sci. 2015;16:23227–23249. doi: 10.3390/ijms161023227. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- Colombo M.L. An update on Vitamin E, tocopherol, and tocotrienol-perspectives. Molecules. 2010;15:2103–2113. doi: 10.3390/molecules15042103. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- Aggarwal B.B., Sundaram C., Prasad S., Kannappan R. Tocotrienols, the Vitamin E of the 21st century: It’s potential against cancer and other chronic diseases. Biochem. Pharmacol. 2010;80:1613–1631. doi: 10.1016/j.bcp.2010.07.043. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- Xia W., Mo H. Potential of tocotrienols in the prevention and therapy of Alzheimer’s disease. J. Nutr. Biochem. 2016;31:1–9. doi: 10.1016/j.jnutbio.2015.10.011. [PubMed] [CrossRef] [Google Scholar]
- Chin K.Y., Pang K.L., Soelaiman I.N. Tocotrienol, and its role in chronic diseases. Adv. Exp. Med. Biol. 2016;928:97–130. [PubMed] [Google Scholar]
- Jiang Q. Natural forms of Vitamin E: Metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic. Biol. Med. 2014;72:76–90. doi: 10.1016/j.freeradbiomed.2014.03.035. [PMC free article] [PubMed] [CrossRef] [Google Scholar]